These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 23382144)

  • 1. Marijuana dependence: not just smoke and mirrors.
    Ramesh D; Schlosburg JE; Wiebelhaus JM; Lichtman AH
    ILAR J; 2011; 52(3):295-308. PubMed ID: 23382144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms.
    Werneck MA; Kortas GT; de Andrade AG; Castaldelli-Maia JM
    CNS Drugs; 2018 Dec; 32(12):1113-1129. PubMed ID: 30361897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical management of cannabis withdrawal.
    Connor JP; Stjepanović D; Budney AJ; Le Foll B; Hall WD
    Addiction; 2022 Jul; 117(7):2075-2095. PubMed ID: 34791767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor.
    Cooper ZD; Haney M
    Addict Biol; 2008 Jun; 13(2):188-95. PubMed ID: 18279497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice.
    Schlosburg JE; Carlson BL; Ramesh D; Abdullah RA; Long JZ; Cravatt BF; Lichtman AH
    AAPS J; 2009 Jun; 11(2):342-52. PubMed ID: 19430909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabis use, abuse, and withdrawal: Cannabinergic mechanisms, clinical, and preclinical findings.
    Kesner AJ; Lovinger DM
    J Neurochem; 2021 Jun; 157(5):1674-1696. PubMed ID: 33891706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.
    Allsop DJ; Copeland J; Lintzeris N; Dunlop AJ; Montebello M; Sadler C; Rivas GR; Holland RM; Muhleisen P; Norberg MM; Booth J; McGregor IS
    JAMA Psychiatry; 2014 Mar; 71(3):281-91. PubMed ID: 24430917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and Pharmacodynamic Characterization of Tetrahydrocannabinol-Induced Cannabinoid Dependence After Chronic Passive Cannabis Smoke Exposure in Rats.
    Ravula A; Chandasana H; Jagnarine D; Wall SC; Setlow B; Febo M; Bruijnzeel AW; Derendorf H
    Cannabis Cannabinoid Res; 2019; 4(4):240-254. PubMed ID: 32042924
    [No Abstract]   [Full Text] [Related]  

  • 9. Behavioral Characterization of the Effects of Cannabis Smoke and Anandamide in Rats.
    Bruijnzeel AW; Qi X; Guzhva LV; Wall S; Deng JV; Gold MS; Febo M; Setlow B
    PLoS One; 2016; 11(4):e0153327. PubMed ID: 27065006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice.
    Varvel SA; Bridgen DT; Tao Q; Thomas BF; Martin BR; Lichtman AH
    J Pharmacol Exp Ther; 2005 Jul; 314(1):329-37. PubMed ID: 15831444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse.
    Haney M; Hart CL; Vosburg SK; Comer SD; Reed SC; Foltin RW
    Psychopharmacology (Berl); 2008 Mar; 197(1):157-68. PubMed ID: 18161012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gabapentin attenuates somatic signs of precipitated THC withdrawal in mice.
    Eckard ML; Kinsey SG
    Neuropharmacology; 2021 Jun; 190():108554. PubMed ID: 33845073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cannabis withdrawal syndrome in patients with cannabis dependence only, and in patients with cannabis and opioid dependence].
    Vorspan F; Guillem E; Bloch V; Bellais L; Sicot R; Noble F; Lepine JP; Gorelick DA
    Encephale; 2011 Sep; 37(4):266-72. PubMed ID: 21981886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence.
    Cooper ZD; Haney M
    Int Rev Psychiatry; 2009 Apr; 21(2):104-12. PubMed ID: 19367504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial.
    Levin FR; Mariani JJ; Brooks DJ; Pavlicova M; Cheng W; Nunes EV
    Drug Alcohol Depend; 2011 Jul; 116(1-3):142-50. PubMed ID: 21310551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of dronabinol for cannabis dependence: two case reports and review.
    Levin FR; Kleber HD
    Am J Addict; 2008; 17(2):161-4. PubMed ID: 18393061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration.
    Schlienz NJ; Lee DC; Stitzer ML; Vandrey R
    Drug Alcohol Depend; 2018 Jun; 187():254-260. PubMed ID: 29689485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The endocannabinoid system as a target for the treatment of cannabis dependence.
    Clapper JR; Mangieri RA; Piomelli D
    Neuropharmacology; 2009; 56 Suppl 1(Suppl 1):235-43. PubMed ID: 18691603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal.
    Allsop DJ; Lintzeris N; Copeland J; Dunlop A; McGregor IS
    Clin Pharmacol Ther; 2015 Jun; 97(6):571-4. PubMed ID: 25777582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marijuana poisoning.
    Fitzgerald KT; Bronstein AC; Newquist KL
    Top Companion Anim Med; 2013 Feb; 28(1):8-12. PubMed ID: 23796481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.